2010-023677-19: Bio-molecular effects of interferon-beta and d-vitamin association |
|
|
| Ongoing | 2 | 15 | Europe | BETAFERON*15CONFEZ 0,25MG/ML+, EXTAVIA*SC 15FL 250MCG/ML+15SI, DIBASE, BETAFERON*15CONFEZ 0,25MG/ML+, EXTAVIA*SC 15FL 250MCG/ML+15SI, DIBASE | AZIENDA OSPEDALIERA S. LUIGI GONZAGA | PATIENT WITH RRMS AND SPMS | | | | |
2020-001892-34: Treatment of COVID-19 by Nebulization of Inteferon Beta 1b added to lopinavir/ritonavir: Feasibility, Efficiency and Safety Study Traitement du COVID-19 : Etude de faisabilité, d’efficacité et de sécurité de l’ajout de Nébubilisation d’Interferon Beta 1b au lopinavir/ritonavir |
|
|
| Not yet recruiting | 2 | 60 | Europe | Inteferon Beta 1b, lopinavir/ritonavir, NaCl, Powder and solvent for solution for injection, Coated tablet, Solution for injection, Extavia, Lopinavir/Ritonavir Mylan, NaCl | CHU Amiens-Picardie, CHU Amiens | Infection SARS-Cov-2 Infection SARS-Cov-2, covid 19 covid 19, Diseases [C] - Virus Diseases [C02] | | | | |
NCT04079088: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) |
|
|
| Withdrawn | 2 | 300 | NA | Placebo, BIIB061, Interferon-beta1, Avonex, Plegridy, Betaferon/Betaseron, Extavia, or Rebif, Glatiramer acetate, Copaxone, Glatopa | Biogen | Relapsing Multiple Sclerosis | 09/24 | 09/24 | | |